Researchers in Somerset are joining others across the UK to test whether CBD can reduce psychotic symptoms in people with Parkinson’s.
Studies suggest cannabidiol may help reduce psychosis, although it has not yet been tested specifically with Parkinson’s patients.
Somerset NHS Foundation Trust said around three in five people with the condition experience symptoms such as hallucinations or delusions. The NHS said the trial could offer a safer option, as current treatments are not effective, safe, or convenient for regular use.
CBD, a chemical found in the cannabis plant, has become popular in recent years as a health supplement.
A total of 120 patients will be recruited across the UK. Participants will be given capsules containing either CBD or a placebo for 12 weeks and will be monitored throughout.
Somerset NHS Foundation Trust is the only centre in the south west taking part, and will also host patients from Devon and Cornwall.
Nishi Singh, a research nurse at Somerset NHS Foundation Trust, said: “I think it’s a really exciting study for our trust to be involved in and it could make a huge difference for patients with Parkinson’s who’re experiencing psychosis.
“We know that not all patients with Parkinson’s have symptoms of psychosis, delusions or hallucinations, but for those who do, it’ll be good to understand whether CBD can have a therapeutic effect in reducing those symptoms.”
Dr Sarah Cleaver, principal investigator for the study, added: “It’s really exciting to be part of a national study looking to improve the quality of life of patients suffering with psychosis alongside their Parkinson’s.
“Our current options for treatment are limited and psychosis can be so debilitating.”
The main trial is in London, with Somerset acting as the regional hub for south west England.
